In Finland, the reimbursed pharmacy retail drug prices are determined by wholesale prices approved by the Pharmaceutical Pricing Board and pharmaceutical pricing scheme (PPS) set in legislation. Since 2017, risk-sharing has been possible in the form of confidential conditional agreement-based reimbursement. Thus far, all such agreements have been economic agreements (EA). Most official list prices of EA products have been in the highest PPS category (wholesale price > €420.47/pack). Due to PPS, EA can result in different retail prices depending on whether a rebate (reduction from the listed retail price, based on proportional wholesale price payback to the payer), discount (simple wholesale price cut) or cost saving (simple retail price cut) is used. To estimate the i] retail price impacts of rebate, discount, or cost saving, and ii] empirical potential savings and rebate. The impacts were estimated for drugs with annual wholesale prices of €1,680 (four three-month packages); €10,000; €20,000; €40,000; and €80,000 (twelve one-month packages). Savings produced by EAs and implied average rebates are approximated using publicly available reimbursement information. First, the Finnish EAs rely on rebates from the official retail prices distorted by the PPS. With the different annual wholesale prices and targeted retail cost savings of 15%, 25%, or 35%, the rebate needs to be significantly higher, at 16.6-17.8%, 27.6-29.7%, or 38.7-41.6% undiscounted, respectively, depending on the wholesale price. Second, savings up to approximately 27% among the EAs were estimated for the first two years. This could mean approximately 30% rebate. CONCLUSION: PPS affects EA-based retail prices. Higher wholesale prices and lower rebates decrease the differences between rebate, discount, and cost cut, demonstrating higher economic efficiency of risk-sharing among high-cost treatments. Rebate calculation for the true cost of a risk-shared drug and tying risk-sharing rebates to effectiveness and discounting are recommended.